

Figure S1. Volume of xenograft tumor  $\leq$ 14 days after inoculation. (A) The maximum diameter is the longitude of xenograft tumors. (B) The volume of xenograft tumor is equal to (long diameter x short diameter x short diameter)/2.




Table SI. Radioactivity in the tumor area using whole-body phosphor autoradiography.

Time, h	Groups	DLU/mm <sup>2</sup>	P-value
24	A549 vs. SK-MES-1	63,210±5,419 vs. 56,410±1,991	0.694
	A549 vs. A549-IgG	63,210±5419 vs. 43,050±2,391	0.023 <sup>a</sup>
	SK-MES-1 vs. A549-IgG	56,410±1,991 vs. 43,050±2,391	0.119
48	A549 vs. SK-MES-1	76,740±3,430 vs. 57,060±3,495	0.015 <sup>a</sup>
	A549 vs. A549-IgG	76,740±3,430 vs. 36,670±2,879	<0.001 <sup>a</sup>
	SK-MES-1 vs. A549-IgG	57,060±3,495 vs. 36,670±2,879	0.014 <sup>a</sup>
72	A549 vs. SK-MES-1	36,620±3,160 vs. 33,780±3,396	0.975
	A549 vs. A549-IgG	36,620±3,160 vs. 22,430±2,226	0.055
	SK-MES-1 vs. A549-IgG	33,780±3,396 vs. 22,430±2,226	0.106

<sup>a</sup>P<0.05. DLU, digital light units.

Table SII. T/NT ratio of  $^{125}\text{I}$ -anti-CD93 monoclonal antibody in xenograft model of non-small cell lung cancer.

Time, h	Groups	T/NT	P-value
24	A549 vs. SK-MES-1	2.42 $\pm$ 0.14 vs. 1.67 $\pm$ 0.27	0.075
	A549 vs. A549-IgG	2.42 $\pm$ 0.14 vs. 1.30 $\pm$ 0.02	0.013 <sup>a</sup>
	SK-MES-1 vs. A549-IgG	1.67 $\pm$ 0.27 vs. 1.30 $\pm$ 0.02	0.550
48	A549 vs. SK-MES-1	4.45 $\pm$ 0.86 vs. 1.97 $\pm$ 0.07	0.043 <sup>a</sup>
	A549 vs. A549-IgG	4.45 $\pm$ 0.86 vs. 1.71 $\pm$ 0.24	0.028 <sup>a</sup>
	SK-MES-1 vs. A549-IgG	1.97 $\pm$ 0.07 vs. 1.71 $\pm$ 0.24	0.897
72	A549 vs. SK-MES-1	2.69 $\pm$ 0.13 vs. 2.02 $\pm$ 0.18	0.142
	A549 vs. A549-IgG	2.69 $\pm$ 0.13 vs. 1.68 $\pm$ 0.25	0.030 <sup>a</sup>
	SK-MES-1 vs. A549-IgG	2.02 $\pm$ 0.18 vs. 1.68 $\pm$ 0.25	0.811

<sup>a</sup>P<0.05. T/NT, target-to-non-target.